Use of ex vivo patient derived tumor organotypic spheroids to identify combination therapies for HER2mutant non small cell lung cancer.

CONCLUSIONS: The XDOTS platform can be used to evaluate therapies and therapeutic combinations ex vivo using PDX tumors. This approach may accelerate the identification and clinical development of therapies for targets with no or few existing models and/or therapies.
PMID: 32034078 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - February 6, 2020 Category: Cancer & Oncology Authors: Ivanova E, Kuraguchi M, Xu M, Portell A, Taus LJ, Diala I, Lalani AS, Choi J, Chambers ES, Li S, Liu S, Chen T, Barbie TU, Oxnard GR, Haworth J, Wong KK, Dahlberg SE, Aref A, Barbie DA, Bahcall M, Paweletz CP, Janne PA Tags: Clin Cancer Res Source Type: research